论文部分内容阅读
目的观察拉贝洛尔辅治妊娠期高血压对母婴预后及血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)水平的影响。方法将220例妊娠期高血压孕妇随机分为观察组和对照组各110例。对照组患者进行常规治疗,观察组患者在常规治疗的基础上给予拉贝洛尔治疗。比较2组母婴预后的情况及患者治疗前后血清Hcy、hs-CRP水平变化。结果观察组产后出血、胎儿窘迫及新生儿窒息的发生率均低于对照组,差异均有统计学意义(P<0.05)。治疗后2组患者的血清Hcy、hs-CRP水平均低于治疗前(P<0.05);且观察组血清Hcy、hs-CRP水平低于对照组,差异均有统计学意义(P<0.05)。结论应用拉贝洛尔辅治妊娠期高血压能够有效降低患者血压,改善患者的临床症状及改善母婴不良结局,降低患者血清Hcy、hs-CRP水平,值得推广应用。
Objective To observe the effects of labetalol on pregnancy-induced hypertension and the levels of serum homocysteine (Hcy) and high-sensitivity C-reactive protein (hs-CRP). Methods 220 pregnant women with gestational hypertension were randomly divided into observation group and control group, with 110 cases each. Patients in the control group were treated routinely, and patients in the observation group were given labetalol on a regular basis. The prognosis of the two groups were compared and the changes of serum Hcy, hs-CRP levels before and after treatment were compared between the two groups. Results The incidence of postpartum hemorrhage, fetal distress and neonatal asphyxia in observation group were lower than those in control group (P <0.05). The levels of Hcy and hs-CRP in the two groups after treatment were lower than those before treatment (P <0.05), and the levels of Hcy and hs-CRP in the observation group were lower than those in the control group (P <0.05) . Conclusion Treatment of pregnancy-induced hypertension with labetalol can effectively reduce the blood pressure, improve the clinical symptoms and improve the maternal and infant adverse outcomes, reduce the serum levels of hcy and hs-CRP, which is worth popularizing and applying.